FutureCure Health Raises ₹104 Crore in Funding Led by Carnelian Asset Management to Expand Vertigo Care
Keywords: FutureCure Health, Carnelian Asset Management, NeuroEquilibrium, Healthtech Funding 2026, Vertigo Treatment India, Super-speciality Healthcare, Series B Funding.
FutureCure Health, a Jaipur-based healthcare technology company specializing in super-speciality care, has successfully raised ₹104 crore (approximately $11.5 million) in a fresh funding round. The investment was led by Carnelian Asset Management LLP, with participation from several other institutional and private investors.
Strategic Use of Funds
The capital infusion will be primarily utilized to scale the company's diagnostic and rehabilitation network. Key focus areas include:
Expansion of NeuroEquilibrium: Strengthening its wholly-owned subsidiary, which is a specialized chain of vertigo and dizziness clinics.
Global Reach: Expanding its footprint beyond the current 16 countries.
New Verticals: Extending technology-led care models to other chronic lifestyle conditions, including migraine and diabetes.
Tech Innovation: Further developing cloud-based remote platforms and deep-tech diagnostic systems to bridge the gap in specialist doctor availability.
About FutureCure Health & NeuroEquilibrium
Founded in 2015 by the husband-and-wife duo Rajneesh Bhandari and Dr. Anita Bhandari, FutureCure Health aims to revolutionize the treatment of balance disorders. Its subsidiary, NeuroEquilibrium, operates more than 300 clinics across India and internationally.
Unlike traditional symptomatic treatments, NeuroEquilibrium uses advanced diagnostic tools to identify the root cause of vertigo—whether it originates in the inner ear, the brain, or balance pathways. To date, the company has enabled the diagnosis and treatment of over 150,000 patients.
"This funding has reinforced our conviction that globally relevant healthcare technologies can be built in India. Precise, scalable diagnostics can democratize super-speciality healthcare and act as a true force multiplier for better outcomes." — Rajneesh Bhandari, Founder, FutureCure Health.
Funding History & Market Position
This latest round follows a $4 million raise in 2022, which saw participation from Kotak Alternate Asset Management, RVCF Ventures, and Unicorn India Ventures. With this new Series B round, FutureCure Health is positioned as a leader in the niche but critical neuro-otology space, addressing a condition that affects nearly six crore people in India alone.